These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 5337082)
1. Neuromuscular pharmacology. Karczmar AG Annu Rev Pharmacol; 1967; 7():241-76. PubMed ID: 5337082 [No Abstract] [Full Text] [Related]
2. [Participation of natural imidazole-containing dipeptides in the biosynthesis and reception of acetylcholine]. Severin SE Usp Sovrem Biol; 1967; 64(2):181-96. PubMed ID: 4321653 [No Abstract] [Full Text] [Related]
3. Some speculations on the chemical nature of postjunctional membrane receptors. Cavallito CJ Fed Proc; 1967; 26(6):1647-54. PubMed ID: 6075904 [No Abstract] [Full Text] [Related]
4. Reduced acetylcholine receptors in myasthenia gravis. Drachman DB; Fambrough DM; Satyamurti S Trans Am Neurol Assoc; 1973; 98():93-5. PubMed ID: 4361781 [No Abstract] [Full Text] [Related]
5. [On the physiology of the medulloneuromotor system from the aspect of neuromuscular blockade with relaxants]. Langrehr D Acta Anaesthesiol Scand Suppl; 1966; 25():193-206. PubMed ID: 6003286 [No Abstract] [Full Text] [Related]
6. [Clinical pharmacology of the neuromuscular junction in myasthenia gravis. (Preliminary communication)]. Jurenić D; Jusić A Neurologija; 1978; 26(1-4):37-9. PubMed ID: 754038 [No Abstract] [Full Text] [Related]
7. [Equilibrium potentials of a postsynaptic membrane activated by various cholinomimetics during changes in the extracellular ionic medium]. Dunin-Barkovskiĭ VL; Kovalev SA; Magazanik LG; Potapova TV; Chaĭlakhian LM Biofizika; 1969; 14(3):485-94. PubMed ID: 5397717 [No Abstract] [Full Text] [Related]
8. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395 [TBL] [Abstract][Full Text] [Related]
9. Adverse drug effects on neuromuscular transmission. Howard JF Semin Neurol; 1990 Mar; 10(1):89-102. PubMed ID: 2161128 [No Abstract] [Full Text] [Related]
10. [Severity of myasthenia gravis is related to the degree of neuromuscular blocking effect by isoflurane]. Kadosaki M; Enzan K; Horiguchi T; Komatsu H; Suzuki M Masui; 1993 Jun; 42(6):906-9. PubMed ID: 8320811 [TBL] [Abstract][Full Text] [Related]
11. Grob on myasthenia gravis. KAHN A J Ark Med Soc; 1963 Jan; 59():317-8. PubMed ID: 13958281 [No Abstract] [Full Text] [Related]
12. [Neuromuscular junction: pharmacology, toxicology and clinical use of neuromuscular blocking agents]. Conte-Camerino D; Siro-Brigiani G Clin Ter; 1975 Mar; 72(5):461-91. PubMed ID: 773593 [No Abstract] [Full Text] [Related]
14. Isolation of the cholinergic receptor protein of Torpedo electric tissue. Molinoff PB; Potter LT Adv Biochem Psychopharmacol; 1972; 6():111-34. PubMed ID: 4341331 [No Abstract] [Full Text] [Related]
15. Neuromuscular transmission with a note on myasthenia gravis. MEAD JC McGill Med J; 1957 Apr; 26(2):88-95. PubMed ID: 13429923 [No Abstract] [Full Text] [Related]
16. THE EFFECT OF INSULIN AND POTASSIUM IN MYASTHENIA GRAVIS. FRENKEL M Arch Neurol; 1963 Nov; 9():447-57. PubMed ID: 14057677 [No Abstract] [Full Text] [Related]
17. Observations on the nature of the neuromuscular block in myasthenia gravis. HARVEY AM; GROB D; JOHNS RJ Trans Assoc Am Physicians; 1954; 67():94-6. PubMed ID: 13216816 [No Abstract] [Full Text] [Related]